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Anu Suomalainen
Anu Suomalainen (Wartiovaara) 
completed her MD degree in 1991, 
and in 1993 defended her PhD thesis 
on mitochondrial DNA mutations in 
diseases, at the University of Helsinki, 
Finland. She relocated to McGill 
University in 1998, and returned to 
Finland in 2001. Her research group 
has been established in Biomedicum-
Helsinki since 2001, and belongs to 
the FinMIT Centre of Excellence of the 
Academy of Finland on mitochondrial 
biogenesis and disease. From 2007 
she has been Sigrid Jusélius Professor 
of Clinical Molecular Medicine. Her 
work has been recognized with 
international awards, including Anders 
Jahre and Europe et Medicin prizes, 
and she is an EMBO member. Since 
the 1990s she has been a pioneer in 
the field of nuclear control of mtDNA 
maintenance, and the genetics of 
mitochondrial disorders. The major 
focus of her research group is to 
discover molecular mechanisms 
underlying primary and secondary 
mitochondrial dysfunction in 
disease, develop models for these 
disorders and to utilize physiological 
knowledge from the models to develop 
therapies for the currently incurable 
mitochondrial disorders.
Why did you end up in science, having 
a medical background? I had been 
determined to become a practising 
clinician, and I did work during and right 
after my MD studies in general health 
care, acute medicine, internal medicine 
and neurology clinics. However, I was 
attracted to research, and I encountered 
important teachers, who added fuel to 
the emerging flames. Early in my PhD 
project, in 1990, my mentors Hannu 
Somer and Matti Haltia urged me to 
travel to NYC, Columbia Presbyterian 
Medical Center, to work with Billi 
DiMauro and Eric Schon, who taught 
me the essentials of mitochondrial 
disorders and genetics, knowledge that 
was just beginning to be established. 
This NYC period established a tight 
scientific friendship and collaboration 
network with colleagues around the 
world, which still is important for my 
work. After NYC, I returned to Finland 
to the lab of Leena Peltonen, who 
provided me with state-of-the-art 
Q & A resources and guidance on molecular genetics, and inspired me with her 
enthusiasm, drive and passion to 
science, which was unique. I stayed in 
her lab until 1998, after which I went 
to do a second postdoc in Canada, 
in Eric Shoubridge’s group. Eric is 
a leader in our field; exceptional in 
his ability to notice an important 
detail, his precision and technical 
perfection, and his fearless tackling of 
any biological question. Leena’s and 
Eric’s surroundings had a big impact 
on getting me completely hooked on 
the molecular basis of disease. Also, I 
soon noticed that it was not realistic to 
lead a competitive research group, do 
simultaneous clinical work, and be a 
mother of three and therefore I left the 
clinics.
What advice would you offer 
someone wondering whether to start
a career in biology? First: if you have 
an interest in science, do not worry 
too much about a specific topic. Get 
yourself involved in an active scientific
environment and good group: search 
for a mentor and supervisor who 
stimulates your mind. Do your PubMed
homework of the potential mentor, 
interview group members in addition to
the group leader, but also follow your 
gut feeling. I only hire people that I like
and similarly, you should only choose a
mentor that you like. Second: science 
is not a nine-to-five job. It is like being 
an artist, it does not count hours and 
it is driven by curiosity. Often you 
fail, sometimes you are stuck with no 
inspiration, and sometimes the result 
is a masterpiece. It requires hard work
and persistence, and a bit of luck. It is 
not easy — even if you are in a good 
lab, no-one else but yourself can do 
a science career for you.  Third: if you 
have the sparkle, just do it!
If you knew what you know earlier 
on, would you still pursue the same 
career path? Yes. Definitely. I got my 
first actual researcher salary only after
completing my PhD. I still remember 
the feeling: privileged and amazed for 
getting paid for my best hobby. I really
like the fact that I do not currently 
know what is the hottest stuff that we 
will be working with in 6 months’ time. 
This work is never routine. 
What is your favorite conference? 
It is hard to single out a specific 
conference. I sometimes am invited 
to congresses that are not exactly on my own field. The most stimulating 
new ideas often come from such 
conferences. The latest conference of 
that kind was the World Congress of 
Neurology in Vienna, and its session 
of neurological consequences of 
malnutrition. 
Do you have a ‘scientific hero’ — if 
so, who and why? Leena Peltonen, my 
supervisor and mentor, who passed 
away at much too early an age in 2010, 
was a great role model for a scientist. 
Her drive, vision and intuition in 
science were impressive. She diligently 
promoted and emphasized excellence 
in science, and used her charisma 
and influence in science politics to 
benefit the scientific community. She 
showed her students the importance 
of popularizing science, educating 
laypeople, and was very good at it: still, 
in Finland, if people on the street have 
to mention a Finnish scientist by name, 
they will name her. 
How do you feel scientific research 
differs in Finland compared with 
other countries? I think that for a small 
country, our biomedical research is at 
an excellent level and the resources are 
good. We still have quite transparent 
funding systems, aiming to fund 
scientific excellence. 
If you could change one thing about 
research in Finland, what would 
it be? With the economic crisis, 
and reducing levels of funding, we 
really should focus on our strengths 
in science, and not try to maintain 
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Pericycle
Tom Beeckman1,2  
and Ive De Smet1,2,3
What is it? The pericycle is a unique 
layer of cells in plants, named after 
its position, encircling the vascular 
tissue in stems and roots. In roots, it is 
surrounded by the inner cortical layer, 
namely the endodermis (Figure 1).
Can it be regarded as a separate 
plant tissue? The pericycle is a 
heterogeneous, non-vascular tissue 
in plants that is divided into two 
populations — one at the xylem pole 
and one at the phloem pole. Pericycle 
cells at these poles are marked by 
differences in size, by ultrastructural 
features and by specific proteins 
and gene expression. Transcriptional 
evidence suggests that pericycle 
cells are intimately associated 
with their underlying vascular 
tissue instead of being a separate 
concentric uniform clonal layer. 
Moreover, distinct functions have 
been attributed to xylem pole 
versus phloem pole pericycle cells, 
countering the idea of a delineated 
plant tissue.
What is the pericycle required for? 
Several different functions have 
been attributed to the pericycle 
both in roots and shoots. In the 
root, it is required for xylem loading 
(for example, BOR1, an efflux-type 
boron transporter for xylem loading, 
is specifically expressed in the 
pericycle). In angiosperm roots, it 
is essential for lateral root initiation 
and later on becomes involved in 
secondary growth. 
What about pericycle and lateral 
root initiation? In most plants, 
including the model species 
Arabidopsis thaliana, lateral root 
initiation occurs at the xylem 
poles (Figure 1). In monocots like 
maize that have multiple xylem 
strands, initiation takes place at 
the phloem poles. Nevertheless, it 
appears that the same or similar 
key molecules are involved in 
regulating the process of lateral 
root initiation in both cases, with 
positional information coming from 
Quick guideeverything. Political guidance of research funding is increasing, and 
more and more targeted funding calls 
are directed to restricted subjects 
and applied sciences. The strength of 
basic research should be maintained, 
and not endangered in search of fast 
commercial applications. 
And what lessons could other 
countries learn from Finland? A 
major difference, when compared, 
for example, to central and southern 
Europe, is gender equality. For 
decades, Finnish women have had 
their jobs outside home, and this 
has been supported by the state: 
we have an excellent and affordable 
communal day-care system and equal 
high-quality basic education systems. 
Being a woman has not hindered my 
scientific career. However, I notice 
the difference, when I travel south. A 
concrete example: I was interviewed 
for the Centre of Excellence call 
when 8 months pregnant. A German 
colleague said that she would never 
have passed the interview in her 
country, looking so pregnant. It 
did not even occur to me that my 
physical appearance or life situation 
would somehow affect the outcome 
of my interview. It did not. We were 
selected for Centre of Excellence of the 
Academy of Finland.
How do you balance basic research 
with translational research in your 
lab? Me being an MD is reflected 
by the fact that all our research 
starts from questions concerning 
disease mechanisms — even if we 
often find ourselves deep in basic 
molecular biology. Therefore, all our 
research has a translational twist. 
Application of our results to patient 
care is straightforward for genetic 
diagnosis and biomarkers — I also 
serve as a Chief Physician in charge 
of mitochondrial disease diagnostics 
at Helsinki University Central Hospital. 
To truly develop new treatments for 
patients, strong basic academic 
research and well-developed 
interactions with pharma companies 
are required. 
Do you have any strong views on 
journals and the peer review system? 
During the last five years, impact factor 
has become increasingly important 
for journals, which affects the editorial 
work: science that makes headlines is 
promoted. This trend worries me. I also think that too much lobbying is allowed
and going on. I have been told that I 
am naive, but I strongly think that the 
data should speak for themselves. 
I very much welcome openness in the
review process. By this, I do not mean 
that anonymity of reviewers should be 
removed, because that would endanger
objectivity — the scientists’ sandbox 
is small. However, some journals 
have opened the reviewer statements 
and revision process to be publicly 
available after acceptance of the article,
which I warmly support. I also like 
the system, used by some editors, in 
which a conflicting review statement is 
forwarded to other reviewers for them 
to comment. This reduces the likelihood
of unjustified paper-trashing by a hastily
done review by ‘the third reviewer’. 
What is your greatest ambition in 
research? To understand the molecula
physiology of energy metabolic 
disorders, the interdependence and 
regulation of different metabolic 
pathways in detail, and to be able 
to apply this knowledge to develop 
therapies for the currently incurable 
disorders. We are not quite there, but 
closer to the goal than ever before.
What do you think are the big 
questions to be answered next in 
your field? The mitochondrial field 
has — for obvious reasons — been 
focusing a lot on the organelle. 
However, it has become increasingly 
evident that interaction and signaling 
between different organelles play a 
major role in disease. Therefore, in fact 
it is hard to define an organelle as an 
isolated system, as lysosomes guide 
mitochondrial biogenesis, mitochondria
tune nuclear transcription, endoplasmic
reticulum defines sites of mitochondrial 
division, etc. Furthermore, single cells 
and tissues may modify the metabolism
of distant organs in the whole organism
through various different levels of 
metabolite and cytokine signaling. The 
metabolic network is dynamic and 
acts locally, distally, in space and in 
time. Input from multiple disciplines is 
required to clarify how such cell- and 
tissue-specific signaling patterns fine-
tune physiology to meet environmental 
demands and how they contribute to 
disease. 
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